Corrigendum: Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia

Brwa Ali Hussein; Alexander Hallner; Lovisa Wennström; Mats Brune; Anna Martner; Kristoffer Hellstrand; Elin Bernson; Fredrik B Thorén

doi:10.3389/fimmu.2021.843461

Corrigendum: Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia

Front Immunol. 2022 Jan 13:12:843461. doi: 10.3389/fimmu.2021.843461. eCollection 2021.

Authors

Brwa Ali Hussein^{1

2}, Alexander Hallner^{1

3}, Lovisa Wennström⁴, Mats Brune⁴, Anna Martner^{1

3}, Kristoffer Hellstrand^{1

3}, Elin Bernson^{1

5}, Fredrik B Thorén^{1

2}

Affiliations

¹ Tumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
² Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
³ Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
⁴ Department of Hematology, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
⁵ Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2021.796072.].

Keywords: NK cell receptors; Re:Mission trial; acute myeloid leukemia; gene variants; histamine/IL-2; immunotherapy; single nucleotide polymorphism.

Publication types

Published Erratum